Our data implies that treatment with EAPB02303 upregulates ARF to induce NPM1 SUMOylation, thereby antagonizing the NPM1-mediated ribosomal biogenesis in NPM1c-AML, necessitating future investigations. This evidence concerns the gene CDKN2A and acute myeloid leukemia.